OTLK
OUTLOOK THERAPEUTICS INCNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$37.46M
P/E Ratio
—
EPS
$-1.13
Beta
0.33
52W High
$3.39
52W Low
$0.16
50-Day MA
$0.27
200-Day MA
$0.98
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
2.85
PEG Ratio
—
About OUTLOOK THERAPEUTICS INC
Outlook Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. The company is headquartered in Cranbury, New Jersey.
Fundamentals
| Revenue (TTM) | 333,140 |
| Gross Profit (TTM) | $-1.20M |
| EBITDA | $-60.45M |
| Operating Margin | -11007.00% |
| Return on Equity | -3.65% |
| Return on Assets | -184.80% |
| Revenue/Share (TTM) | $0.01 |
| Book Value | $-0.60 |
| Price-to-Book | 38.42 |
| Price-to-Sales (TTM) | 112.43 |
| EV/Revenue | 170.82 |
| EV/EBITDA | -4.13 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 658.00% |
| Shares Outstanding | $120.86M |
| Float | $105.53M |
| % Insiders | 15.52% |
| % Institutions | 9.17% |
Analyst Ratings
Consensus ($4.17 target)
2
Buy1
HoldMore HEALTHCARE Stocks
Data last updated: 5/25/2026